Van Hulzen Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-50
Closed -$6.16K – 712
2024
Q4
$6.16K Buy
+50
New +$5.89K ﹤0.01% 826
2023
Q1
– Sell
-2,631
Closed -$419K – 314
2022
Q4
$419K Buy
2,631
+109
+4% +$16K 0.05% 195
2022
Q3
$336K Sell
2,522
-3,145
-55% -$478K 0.04% 200
2022
Q2
$884K Sell
5,667
-412
-7% -$63.4K 0.11% 118
2022
Q1
$946K Buy
6,079
+207
+4% +$30K 0.1% 118
2021
Q4
$748K Buy
5,872
+1,095
+23% +$144K 0.08% 138
2021
Q3
$622K Buy
4,777
+1,931
+68% +$292K 0.09% 121
2021
Q2
$506K Buy
2,846
+189
+7% +$32.7K 0.08% 147
2021
Q1
$437K Buy
2,657
+40
+2% +$6.58K 0.07% 159
2020
Q4
$432K Buy
2,617
+98
+4% +$14.6K 0.07% 159
2020
Q3
$359K Buy
+2,519
New +$312K 0.05% 172
2020
Q1
– Sell
-10,460
Closed -$1.56M – 272
2019
Q4
$1.56M Buy
+10,460
New +$1.42M 0.3% 72

Other funds holding JAZZ

Van Hulzen Asset Management's JAZZ Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 50 shares — an estimated $6.16K sold.

Van Hulzen Asset Management first reported a position in JAZZ in Q4 2019 and held it in 12 quarters. The position peaked at $1.56M in Q4 2019. 551 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Van Hulzen Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 50 Jazz Pharmaceuticals shares in Q1 2025, an estimated $6.16K.
  • Van Hulzen Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2019 and held it in 12 quarters.
  • Van Hulzen Asset Management's Jazz Pharmaceuticals position peaked at $1.56M in Q4 2019.
  • 551 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.